Richard Rychlik - 14 Mar 2024 Form 4 Insider Report for Armata Pharmaceuticals, Inc. (ARMP)

Reporting relationship: Corporate Controller and PFO
Issuer ticker: ARMP
Reported as of: 14 Mar 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Mar 2024, 20:02:52 UTC
Prior SEC filing: 26 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Richard Rychlik

Key filing fact

Richard Rychlik filed Form 4 for Armata Pharmaceuticals, Inc. (ARMP) on 18 Mar 2024.

Key facts

This page summarizes Richard Rychlik's Form 4 filing for Armata Pharmaceuticals, Inc. (ARMP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Mar 2024, 20:02.

Change

Previous filing in this sequence was filed on 26 Dec 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARMP transaction

Common Stock

Award

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 14 Mar 2024
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARMP transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 14 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $3.38
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Twenty-five percent (25%) of the Stock Options shall vest on March 14th of each of 2025, 2026, 2027, and 2028.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .